International Alzheimer’s study fails

24 February 2020 | 9:12 am
Initial analysis from an international clinical trial has indicated that the investigational drugs didn’t slow memory loss, cognitive decline in rare, inherited Alzheimer’s. The clinical trial evaluating whether two investigational drugs can slow memory loss and cognitive decline in people in the early stages of a rare, inherited form of Alzheimer’s disease has yielded disappointing […]

Changes in Xbrane’s management team

24 February 2020 | 8:35 am
Xbrane team
Xbrane Biopharma strengthens its management team to better equip the company for commercialization of its biosimilars and Paolo Sarmientos steps out of the management team. Xbrane Biopharma is advancing its portfolio of biosimilars with targeted launch of leading product Xlucane (Lucentis biosimilar) in 2022. To better equip the company for commercialization of its biosimilars Xbrane […]

SciLifeLab fellows appointed Future Research Leaders by the Swedish Foundation for Strategic Research

21 February 2020 | 9:07 am
Elsser and Sellin
The Swedish Foundation for Strategic Research (SSF) has appointed the seventh generation of Future Research Leaders (FFL). From the 227 applications, 10 men and 10 women were selected, among them SciLifeLab Fellows Simon Elsässer (Karolinska Institutet) and Mikael Sellin (Uppsala University). The goal is to support and promote young scientists into becoming the future leaders […]

Olli Pi­etiläinen re­cruited new Group Leader to Neuroscience Cen­ter in Helsinki

21 February 2020 | 9:00 am
Olli Pietiläinen has been appointed as a group leader to the Neuroscience Center (NC) in Helsinki. Pietiläinen received his PhD in Molecular Genetics from the University of Helsinki, while also spending several years at the Wellcome Trust Sanger Institute in Cambridge, UK. For his postdoc, Pietiläinen moved to the Broad Institute and Harvard University, Cambridge, […]

In-depth analysis of InDex Pharmaceuticals’ CONDUCT study

20 February 2020 | 12:33 pm
InDex Pharmaceuticals has announced the conclusions from in-depth analysis of the complete data set from the phase IIb dose optimisation study CONDUCT, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The analysis confirms that the highest dose tested, which met the primary endpoint of the study, demonstrates an […]

Scandinavian Biopharma secures 10.6 million EUR

20 February 2020 | 8:25 am
Scandinavian Biopharma secures 10.6 million EUR
Scandinavian Biopharma has been awarded a 10.6 million EUR grant from EDCTP in international competition for the planned Phase III clinical trial of the ETEC vaccine candidate ETVAX. The EDCTP grant is a part of the European Framework Programme for Research and Innovation, Horizon 2020. Make the vaccine preparation more fieldable and user-friendly The project […]

First patient enrolled in Ascelia’s Phase III study

20 February 2020 | 8:19 am
Ascelia Pharma has announced that the first patient has been enrolled in the company’s global Phase III clinical study SPARKLE with Mangoral in patients with severely reduced renal function and with known or suspected liver lesions. “It is an important event for patients seeking a safe agent to detect liver lesions that this pivotal Phase […]

Cantargia completes a directed share issue of approximately 410 million SEK

20 February 2020 | 7:57 am
Cantargia completes a directed share issue of approximately 410 million SEK
Through the Directed Share Issue, Cantargia will receive proceeds amounting to approximately SEK 410 million before transaction related costs. Investors in the Directed Share Issue are a wide range of Swedish and international investors including new investors such as Swedbank Robur, HBM Healthcare Investments, Granite Point Capital and Unionen as well as current shareholders such […]

AstraZeneca and IBM collaborate in order to strengthen digital health expertise

19 February 2020 | 8:03 pm
AstraZeneca BioVentureHub
AstraZeneca’s BioVentureHub has entered into a new collaboration with IBM Sweden. The collaboration gives small and mid-sized companies connected to IBM Sweden or AstraZeneca’s BioVentureHub access to each others’ open platforms for innovation. The collaboration aims to stimulate growth of small and mid-sized companies, to support knowledge exchange between life sciences and digital technology, and […]

15 million SEK invested in MediTuner

19 February 2020 | 8:16 am
Björn Nordlund Photo Rikard Häggbom
15 million SEK has been invested in MediTuners’s digital asthma-app. Almi Invest is investing 3 million SEK in MediTuner and its app AsthmaTuner, developed together with Karolinska Institutet. The app is connected to a spirometry and provides asthma patients with an automatic treatment recommendation. In this emission consisting of 15 million SEK a number of […]